Subhash Ramakrishnan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Subhash Ramakrishnan has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Amy Yu
National Cancer Institute 12 Pediatric Oncology Branch, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
9 shared publications - Angela Kim
Department of Pathology and Molecular Medicine, Yale School of Medicine, New Haven, Connecticut
9 shared publications - Charles Brenner
Department of Diabetes and Cancer Metabolism, Beckman Research Institute, Duarte, CA, USA; Sustainable Wellbeing Across Lifespan, Faculties of Medicine and Pharmacy and the Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
9 shared publications - Christine M. Heske
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
9 shared publications - Collin D. Heer
Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut
9 shared publications - David Hall
Children's Oncology Group, Monrovia, CA
9 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
NAPRT-deficient RMS models are sensitive to FK866 and cannot be rescued with NA
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
NAPRT-deficient RMS models are sensitive to FK866 and cannot be rescued with NA
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Functional validation of single-cell clones of CRISPR/Cas9 ribonucleoprotein (RNP) based NAPRT knock-out model
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Functional validation of single-cell clones of CRISPR/Cas9 ribonucleoprotein (RNP) based NAPRT knock-out model
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 2. NAPRT-deficient RMS models are not able to utilize NA to rescue cell viability
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 2. NAPRT-deficient RMS models are not able to utilize NA to rescue cell viability
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 3. Generation of plasmid based NAPRT overexpressing isogenic model.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 3. Generation of plasmid based NAPRT overexpressing isogenic model.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 7. Clinical Correlates of NAPRT Expression in RMS patient samples.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 7. Clinical Correlates of NAPRT Expression in RMS patient samples.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Tables with list of antibodies and description of TMAs
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Tables with list of antibodies and description of TMAs
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 5. Induction of apoptosis in RMS models with OT-82 treatment
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 5. Induction of apoptosis in RMS models with OT-82 treatment
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 6. Tumor volumes in RMS isogenic models after OT-82 treatment.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
Supplementary Figure 6. Tumor volumes in RMS isogenic models after OT-82 treatment.
- 18 May 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (10) , OF1-OF14
NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
New treatments are needed to improve survival in children with rhabdomyosarcoma (RMS). Nicotinamide adenine dinucleotide (NAD+) biosynthesis, regulated by the enzymes nicotinic acid phosphoribosyltransferase (NAPRT) and nicotinamide phosphoribosyltransferase (NAMPT), represents a metabolic vulnerability due to high NAD+ turnover in cancers. Although NAMPT inhibitors (NAMPTi) show preclinical promise, clinical translation has been limited by toxicity and the lack of predictive biomarkers. In this study, we evaluated NAPRT expression in RMS and its potential as an actionable biomarker to guide NAMPTi therapy. NAPRT promoter methylation, transcript levels, and protein expression were assessed in RMS cells, patient-derived xenografts (PDX), and primary tumors (n = 109) from the Children’s Oncology Group. In vitro sensitivity to NAMPTi was tested in isogenic RMS cell lines, examining the role of NAPRT expression in mediating cytotoxicity and the ability of nicotinic acid (NA) to rescue viability. In vivo efficacy was assessed using cell-derived, NAPRT-isogenic, and orthotopic PDX models. NAPRT promoter hypermethylation was found in a subset of RMS models and patient samples. Immunohistochemistry showed loss of NAPRT protein in 30% to 40% of tumors, defined as <1% tumor cell staining. Methylation modestly correlated with protein expression. NAPRT-deficient cells were highly sensitive to NAMPTi, driven by NAD+ depletion and not reversible with NA. In vivo, NAMPTi induced significant tumor regression, which was not abrogated with NA administration in NAPRT-deficient models. NAPRT loss occurs in a subset of RMS and may offer a biomarker-driven strategy to expand the therapeutic window of NAMPTi. Further research is needed to understand NAPRT regulation and optimize biomarker assays in future clinical trials.
- 18 May 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (10) , OF1-OF14
NAPRT Expression and Epigenetic Regulation in Pediatric Rhabdomyosarcoma as a Potential Biomarker for NAMPT Inhibition
New treatments are needed to improve survival in children with rhabdomyosarcoma (RMS). Nicotinamide adenine dinucleotide (NAD+) biosynthesis, regulated by the enzymes nicotinic acid phosphoribosyltransferase (NAPRT) and nicotinamide phosphoribosyltransferase (NAMPT), represents a metabolic vulnerability due to high NAD+ turnover in cancers. Although NAMPT inhibitors (NAMPTi) show preclinical promise, clinical translation has been limited by toxicity and the lack of predictive biomarkers. In this study, we evaluated NAPRT expression in RMS and its potential as an actionable biomarker to guide NAMPTi therapy. NAPRT promoter methylation, transcript levels, and protein expression were assessed in RMS cells, patient-derived xenografts (PDX), and primary tumors (n = 109) from the Children’s Oncology Group. In vitro sensitivity to NAMPTi was tested in isogenic RMS cell lines, examining the role of NAPRT expression in mediating cytotoxicity and the ability of nicotinic acid (NA) to rescue viability. In vivo efficacy was assessed using cell-derived, NAPRT-isogenic, and orthotopic PDX models. NAPRT promoter hypermethylation was found in a subset of RMS models and patient samples. Immunohistochemistry showed loss of NAPRT protein in 30% to 40% of tumors, defined as <1% tumor cell staining. Methylation modestly correlated with protein expression. NAPRT-deficient cells were highly sensitive to NAMPTi, driven by NAD+ depletion and not reversible with NA. In vivo, NAMPTi induced significant tumor regression, which was not abrogated with NA administration in NAPRT-deficient models. NAPRT loss occurs in a subset of RMS and may offer a biomarker-driven strategy to expand the therapeutic window of NAMPTi. Further research is needed to understand NAPRT regulation and optimize biomarker assays in future clinical trials.
- Open Access
- 16 March 2026
- Published by Elsevier in SSRN Electronic Journal
Leveraging Large Language Models to Extract Prognostic Pathology Features in Ewing Sarcoma
Background: Current risk stratification for Ewing sarcoma relies heavily on clinical factors such as metastatic status, failing to capture histologic heterogeneity as a potential prognostic indicator. Although pathology reports contain rich biological data, this information remains locked in unstructured narrative text, limiting large-scale retrospective analyses. We aimed to validate the utility of Large Language Models (LLMs) for scalable data abstraction and to identify prognostic histologic features from a large multi-institutional cohort.Methods: We conducted a retrospective cohort study using data from six Children’s Oncology Group (COG) clinical trials. We utilized an LLM-based pipeline (OpenAI o3) to extract structured variables—including immunohistochemical (IHC) markers and CD99 staining patterns—from digitized, Optical Character Recognition (OCR)-processed pathology reports. Extraction accuracy was validated against a human-annotated ground truth (n=200) and cross-validated against senior experts (n=48). We assessed the association between extracted features and Overall Survival (OS) using Kaplan-Meier analysis and multivariable Cox proportional hazards regression, adjusting for metastatic status.Findings: We analyzed 931 diagnostic pathology reports from 185 institutions spanning over 21-years. The LLM achieved a weighted average accuracy of 94% across 17 IHC markers; in a cross-validation subset, the LLM outperformed human annotators (weighted average accuracy over 15 IHC markers: LLM o3: 98.1%, a pediatric resident 91.4%, and a pediatric oncologist 95.9%). Survival analysis identified Neuron-Specific Enolase (NSE) and S100 as significant prognostic biomarkers. After adjusting for metastatic status, NSE positivity was associated with significantly inferior survival (HR 2.15, 95% CI 1.15–4.02, p=0.016); this risk was most pronounced in patients with non-metastatic disease (HR 5.64, p=0.0055). Conversely, S100 positivity was associated with improved survival (HR 0.58, 95% CI 0.34–1.00, p=0.046).Interpretation: LLM-assisted extraction of pathology variables is highly accurate and scalable, capable of unlocking "dark data" from historical clinical trials. We identified NSE as a potent risk factor and S100 as a protective marker in Ewing sarcoma, particularly in localized disease. These findings suggest that AI-derived histologic data can refine risk stratification and, if validated, warrant inclusion in future prospective trials.
- 16 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLeveraging Large Language Models to Extract Prognostic Pathology Features in Ewing Sarcoma
Background: Current risk stratification for Ewing sarcoma relies heavily on clinical factors such as metastatic status, failing to capture histologic heterogeneity as a potential prognostic indicator. Although pathology reports contain rich biological data, this information remains locked in unstructured narrative text, limiting large-scale retrospective analyses. We aimed to validate the utility of Large Language Models (LLMs) for scalable data abstraction and to identify prognostic histologic features from a large multi-institutional cohort.Methods: We conducted a retrospective cohort study using data from six Children’s Oncology Group (COG) clinical trials. We utilized an LLM-based pipeline (OpenAI o3) to extract structured variables—including immunohistochemical (IHC) markers and CD99 staining patterns—from digitized, Optical Character Recognition (OCR)-processed pathology reports. Extraction accuracy was validated against a human-annotated ground truth (n=200) and cross-validated against senior experts (n=48). We assessed the association between extracted features and Overall Survival (OS) using Kaplan-Meier analysis and multivariable Cox proportional hazards regression, adjusting for metastatic status.Findings: We analyzed 931 diagnostic pathology reports from 185 institutions spanning over 21-years. The LLM achieved a weighted average accuracy of 94% across 17 IHC markers; in a cross-validation subset, the LLM outperformed human annotators (weighted average accuracy over 15 IHC markers: LLM o3: 98.1%, a pediatric resident 91.4%, and a pediatric oncologist 95.9%). Survival analysis identified Neuron-Specific Enolase (NSE) and S100 as significant prognostic biomarkers. After adjusting for metastatic status, NSE positivity was associated with significantly inferior survival (HR 2.15, 95% CI 1.15–4.02, p=0.016); this risk was most pronounced in patients with non-metastatic disease (HR 5.64, p=0.0055). Conversely, S100 positivity was associated with improved survival (HR 0.58, 95% CI 0.34–1.00, p=0.046).Interpretation: LLM-assisted extraction of pathology variables is highly accurate and scalable, capable of unlocking "dark data" from historical clinical trials. We identified NSE as a potent risk factor and S100 as a protective marker in Ewing sarcoma, particularly in localized disease. These findings suggest that AI-derived histologic data can refine risk stratification and, if validated, warrant inclusion in future prospective trials.